Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Diana Brixner

Showing results (51-60 of 102) with videos related to

Pageof 11
Sort By:
American Health & Drug Benefits|April 12, 2019
The Challenge of Variable Costs in Decisions Based on Cost-Effectiveness Evidence: A Case Study for BrodalumabDiana Brixner, Gary Oderda, Joseph Biskupiak, et al.
Current Medical Research and Opinion|July 31, 2024
Modeling the population health impact of incorporating a multi-cancer early detection (MCED) test to existing cancer screening among immunocompromised individualsChia Jie Tan, Sabrina Ilham, Connor Willis, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|March 17, 2015
Need for multicriteria evaluation of generic drug policiesZoltán Kaló, Anke-Peggy Holtorf, Rafael Alfonso-Cristancho, et al.
BMC Health Services Research|January 13, 2021
Estimation of healthcare-related charges in women with BRCA mutations and breast cancerJoseph Biskupiak, Sudhir Unni, Claire Telford, et al.
Health Policy (Amsterdam, Netherlands)|April 5, 2021
The Role of Patient Experience in the Value Assessment of Complex Technologies - Do HTA Bodies Need to Reconsider How Value is Assessed?Grammati Sarri, Andreas Freitag, Boglarka Szegvari, et al.
Journal of Managed Care & Specialty Pharmacy|April 12, 2021
Sustained long-term benefits of patient support program participation in immune-mediated diseases: improved medication-taking behavior and lower risk of a hospital visitA Mark Fendrick, Diana Brixner, David T Rubin, et al.
Leukemia Research and Treatment|January 20, 2016
Effectiveness and Cost-Effectiveness of Sequential Treatment of Patients with Chronic Myeloid Leukemia in the United States: A Decision AnalysisUrsula Rochau, Martina Kluibenschaedl, David Stenehjem, et al.
Applied Health Economics and Health Policy|April 22, 2011
Patent extension policy for paediatric indications: an evaluation of the impact within three drug classes in a state Medicaid programmeRichard E Nelson, Carrie McAdam-Marx, Megan L Evans, et al.
Journal of Managed Care & Specialty Pharmacy|November 22, 2021
Payer perceptions on the use of patient-reported outcomes in oncology decision makingGary Oderda, Diana Brixner, Joseph Biskupiak, et al.
Journal of Managed Care & Specialty Pharmacy|May 14, 2019
Patient Support Program Increased Medication Adherence with Lower Total Health Care Costs Despite Increased Drug SpendingDiana Brixner, David T Rubin, Philip Mease, et al.
Pageof 11

Showing results (51-60 of 102) with videos related to

Sort By:
Pageof 11
American Health & Drug Benefits|April 12, 2019
The Challenge of Variable Costs in Decisions Based on Cost-Effectiveness Evidence: A Case Study for BrodalumabDiana Brixner, Gary Oderda, Joseph Biskupiak, et al.
Current Medical Research and Opinion|July 31, 2024
Modeling the population health impact of incorporating a multi-cancer early detection (MCED) test to existing cancer screening among immunocompromised individualsChia Jie Tan, Sabrina Ilham, Connor Willis, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|March 17, 2015
Need for multicriteria evaluation of generic drug policiesZoltán Kaló, Anke-Peggy Holtorf, Rafael Alfonso-Cristancho, et al.
BMC Health Services Research|January 13, 2021
Estimation of healthcare-related charges in women with BRCA mutations and breast cancerJoseph Biskupiak, Sudhir Unni, Claire Telford, et al.
Health Policy (Amsterdam, Netherlands)|April 5, 2021
The Role of Patient Experience in the Value Assessment of Complex Technologies - Do HTA Bodies Need to Reconsider How Value is Assessed?Grammati Sarri, Andreas Freitag, Boglarka Szegvari, et al.
Journal of Managed Care & Specialty Pharmacy|April 12, 2021
Sustained long-term benefits of patient support program participation in immune-mediated diseases: improved medication-taking behavior and lower risk of a hospital visitA Mark Fendrick, Diana Brixner, David T Rubin, et al.
Leukemia Research and Treatment|January 20, 2016
Effectiveness and Cost-Effectiveness of Sequential Treatment of Patients with Chronic Myeloid Leukemia in the United States: A Decision AnalysisUrsula Rochau, Martina Kluibenschaedl, David Stenehjem, et al.
Applied Health Economics and Health Policy|April 22, 2011
Patent extension policy for paediatric indications: an evaluation of the impact within three drug classes in a state Medicaid programmeRichard E Nelson, Carrie McAdam-Marx, Megan L Evans, et al.
Journal of Managed Care & Specialty Pharmacy|November 22, 2021
Payer perceptions on the use of patient-reported outcomes in oncology decision makingGary Oderda, Diana Brixner, Joseph Biskupiak, et al.
Journal of Managed Care & Specialty Pharmacy|May 14, 2019
Patient Support Program Increased Medication Adherence with Lower Total Health Care Costs Despite Increased Drug SpendingDiana Brixner, David T Rubin, Philip Mease, et al.
Pageof 11